SS-31 50 mg

Dragon Pharma SS-31

Modern performance research increasingly focuses on mitochondrial health—the core energy systems that drive muscular output, endurance, and recovery. SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide developed to protect and optimize mitochondrial function at its source. Unlike conventional antioxidants, SS-31 selectively localizes to the inner mitochondrial membrane, where it binds to cardiolipin and helps stabilize the electron transport chain. This targeted mechanism has made SS-31 a valuable research compound in studies of cellular energy production, oxidative stress, and exercise-related fatigue. When you Buy SS-31 by Dragon Pharma, you are obtaining a research-grade peptide widely used in mitochondrial and performance-focused research models.

SS-31 Composition

This 2 mL vial contains 50 mg of high-purity SS-31 supplied as a lyophilized powder. SS-31 is a synthetic tetrapeptide (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH₂) specifically engineered to accumulate inside mitochondria rather than dispersing throughout the cell. Research shows SS-31 can reach mitochondrial concentrations thousands of times higher than cytoplasmic levels, allowing it to exert protective effects precisely where oxidative stress originates. The 50 mg concentration supports flexible dosing across short- and long-term research protocols.

Mechanism of Action: Mitochondrial Stabilization

SS-31 acts by binding to cardiolipin, a phospholipid essential for maintaining mitochondrial membrane integrity and efficient electron transport. Under stress conditions, cardiolipin oxidation disrupts ATP synthesis and increases reactive oxygen species (ROS) generation. SS-31 helps preserve cardiolipin structure, supporting mitochondrial stability and energy production. Key mechanisms include:

• Improved Electron Transport Efficiency: Stabilizes oxidative phosphorylation, increasing ATP output while limiting electron leakage.
• Reduced Mitochondrial ROS: Attenuates ROS generation at major mitochondrial complexes.
• Membrane Potential Preservation: Helps maintain mitochondrial membrane potential necessary for sustained energy production.
• Mitophagy Regulation: Supports removal of damaged mitochondria via PINK1/Parkin-mediated pathways.
• Inflammation Modulation: Reduces mitochondrial-driven inflammatory signaling linked to oxidative stress.

Relevance for Athletes & Bodybuilders

In athletic and bodybuilding research, SS-31 is studied for its role in supporting cellular energy efficiency during high training loads. Intensive exercise increases mitochondrial stress, which can impair recovery and performance over time. By improving mitochondrial efficiency and reducing oxidative burden, SS-31 has been investigated in models related to endurance, muscle resilience, and recovery capacity.

• Improved exercise tolerance and fatigue resistance in aging and stress models
• Enhanced mitochondrial efficiency following muscle injury
• Reduction of exercise-induced oxidative damage
• Support for muscle cell viability under high metabolic demand

Research Applications

SS-31 has been widely explored in preclinical research due to its broad mitochondrial activity:

• Muscle & Exercise Research: Studied for endurance, recovery, and mitochondrial efficiency
• Renal Protection Models: Investigated in oxidative and ischemic kidney injury
• Neurodegenerative Research: Examined for neuronal mitochondrial preservation
• Reproductive & Cellular Aging Studies: Researched for mitochondrial health in aging tissues
• Cardiovascular Research: Explored for endothelial mitochondrial protection

Dosage (Men)

SS-31 dosing in research settings is extrapolated from animal and early clinical data. Typical experimental protocols range from 10–40 mg per day administered subcutaneously, with cycles lasting 4–8 weeks. Due to its cumulative mitochondrial effects, consistent daily or alternate-day administration is commonly used in endurance and recovery research models.

Dosage (Women)

Female research protocols generally mirror male dosing but often begin at the lower end (5–20 mg per day) to assess tolerance. Cycles typically last 4–8 weeks depending on study design and metabolic demand.

Active Life

Although SS-31 has a short plasma half-life, its mitochondrial effects persist due to cardiolipin binding and improved mitochondrial turnover. Research supports regular dosing schedules rather than continuous infusion to maintain mitochondrial benefits.

SS-31 Side Effects

SS-31 has demonstrated a favorable safety profile in clinical and preclinical research. Mild injection-site irritation is the most commonly reported effect. At higher experimental doses, transient flushing or gastrointestinal discomfort has been observed. Its targeted mitochondrial mechanism limits systemic side effects.

SS-31 Contraindications / Precautions

Caution is advised in research involving mitochondrial disorders or cancer models due to SS-31's role in cellular survival pathways. This compound is intended for laboratory research only and is not approved for human consumption. Proper handling procedures are required.

Overdosage

Excessive dosing may increase transient adverse effects. No specific antidote exists; supportive monitoring is recommended if unexpected reactions occur.

SS-31 Stack / Cycle

SS-31 is frequently combined with compounds targeting complementary metabolic pathways. Common research stacks include pairing SS-31 with NAD+ to support mitochondrial substrate availability, MOTS-c for mitochondrial signaling research, or AICAR for AMPK-mediated energy regulation. Typical research cycles last 4–8 weeks.

Package Presentation

SS-31 50 mg is supplied in a sterile, sealed 2 mL glass vial containing a white to off-white lyophilized powder. Each vial is labeled with batch number and expiration date to ensure authenticity and quality control.

Storage

Store unreconstituted vials in a cool, dry environment. Refrigeration (2–8°C) is recommended for extended storage. After reconstitution, store refrigerated and use within 28 days.

SS-31 Referrers

Scientific literature continues to highlight SS-31's role in mitochondrial protection. A 2025 study published in the Journal of Vascular Research demonstrated improved mitochondrial localization, reduced oxidative damage, and enhanced cellular survival in oxidative stress models. Read the study on PubMed.